FibroBiologics files US patent application for cell-based alternative to GLP-1 injections

FibroBiologics has filed a US patent application for technology designed to produce GLP-1 and other therapeutic peptides inside the body, as a cell-based alternative to repeated GLP-1 injections. The application covers GLP-1, GIP and GLP-2 class peptides, establishing a broad therapeutic platform.

Detected & updated continuously · Source: Nebula